Naltrexone HCl/bupropion HCl’s dual mechanism supports sustainable weight loss in a patient with obesity and emotional eating

Obesity is a serious chronic health condition that contributes significantly to morbidity and mortality worldwide. According to the 2024 National Health and Morbidity Survey, one in two Malaysian adults are either overweight or obese (53.6%). Current treatment recommendations for obesity include lifestyle interventions, bariatric surgery and pharmacological therapies. Pharmacological options primarily consist of subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonists and oral drugs such as phentermine and naltrexone HCl/bupropion HCl(N/B).